Ionis Pharmaceuticals (IONS) Innovation Day 2025 summary

Strategic vision and growth outlook

• Focused on becoming a fully integrated, commercial-stage biotech, prioritizing wholly owned pipeline and independent launches in neurology and cardiometabolic diseases, targeting both rare and prevalent conditions.

• Achieved or exceeded all key milestones, including six positive phase III readouts, two independent launches within nine months, and four independent launches in the past two years.

• Pipeline includes 10 late-stage medicines, with a steady cadence of phase III data readouts and launches planned through 2027, and four partner launches by end of 2027.

• Ongoing investment in RNA-targeted therapeutics, siRNA, gene editing, and delivery innovations to maintain leadership and expand therapeutic reach.

• Commercial infrastructure built to support current and future launches, leveraging omnichannel and patient support programs, and designed for scalability.

Key product launches and clinical data

• TRYNGOLZA (olezarsen) launched for FCS in the US and approved in the EU, showing strong efficacy in reducing triglycerides (up to 72%) and acute pancreatitis (up to 85%), with positive patient and HCP feedback.

• DAWNZERA (donidalorsen) launched in the US for hereditary angioedema, offering robust efficacy, improved tolerability, and convenient dosing, with EU launch anticipated in 2026.

• Zilganersen pivotal study for Alexander disease showed 33% stabilization in 10m walk test, with NDA submission planned for Q1 2026 and first neurology launch expected in 2026.

• ION582 for Angelman syndrome received Breakthrough Therapy designation, with long-term data showing improvement in expressive communication and pivotal Phase 3 enrollment expected to complete in 2026.

• ION775, an advanced siRNA for SHTG, showed durable triglyceride reductions in Phase 1 and is advancing to Phase 2, with study initiation planned for 2026.

Financial outlook and growth strategy

• Commercial execution for TRYNGOLZA in FCS generated $19M in Q2, with FY2025 guidance of $75M-$80M and strong payer access.

• Accelerating revenue growth driven by recent launches and late-stage pipeline, with >$5B potential annual peak revenue (>$3B from independent products, >$2B from royalties).

• Maintains strong financial position with approximately $2B in cash and short-term investments as of 2025 guidance.

• Clear path to sustained positive cash flow, targeting breakeven by 2028, supported by disciplined capital management.

• Multiple blockbuster opportunities in the pipeline, with independent and partner launches expected to generate over $5B in combined annual peak revenue.